STOCK TITAN
  1. Home
  2. Sec-filings
  3. HAE
  4. [Form 4] HAEMONETICS CORP Insider Trading Activity

[Form 4] HAEMONETICS CORP Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Haemonetics EVP and COO Frank Chan received an equity award and had shares withheld for taxes. On May 15, 2026, he was granted 27,535 restricted stock units (RSUs) under the company’s long-term incentive plan. Each RSU represents a right to receive one share of common stock when it vests.

The RSUs vest over three years, with 40% vesting on the first anniversary of the grant date, another 40% on the second anniversary, and the remaining 20% on the third anniversary. On the same date, 546 shares were disposed of at $56.29 per share to satisfy tax obligations related to vesting of previously granted RSUs, rather than through an open-market sale.

After these transactions, Chan directly owned 32,936 shares of Haemonetics common stock. This figure includes unvested RSUs and shares acquired through the Haemonetics Corporation 2007 Employee Stock Purchase Plan, including 139 shares bought on October 31, 2025 and 119 shares bought on April 30, 2026.

Positive

  • None.

Negative

  • None.
Insider Chan Frank
Role EVP, Chief Operating Officer
Type Security Shares Price Value
Tax Withholding Common Stock 546 $56.29 $31K
Grant/Award Common Stock 27,535 $0.00 --
Holdings After Transaction: Common Stock — 5,401 shares (Direct, null)
Footnotes (1)
  1. Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. This number includes unvested RSUs previously reported, 139 shares acquired by the reporting person on October 31, 2025 under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time, the "ESPP") and 119 shares acquired by the reporting person on April 30, 2026 under the ESPP. The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
RSU grant size 27,535 shares Equity award granted on May 15, 2026
Tax withholding shares 546 shares Withheld to cover RSU-related tax obligations
Tax withholding price $56.29 per share Value used for 546 shares withheld
Shares owned after transactions 32,936 shares Direct holdings following Form 4 transactions
ESPP purchase October 31, 2025 139 shares Acquired under 2007 Employee Stock Purchase Plan
ESPP purchase April 30, 2026 119 shares Acquired under 2007 Employee Stock Purchase Plan
RSU vesting schedule 40% / 40% / 20% Vests on first, second, third anniversaries of grant
restricted stock units ("RSUs") financial
"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Employee Stock Purchase Plan financial
"139 shares acquired by the reporting person on October 31, 2025 under the Haemonetics Corporation 2007 Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Long-Term Incentive Compensation Plan financial
"RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan"
contingent right financial
"Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested"
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Chan Frank
(Last)(First)(Middle)
125 SUMMER STREET
(Street)
BOSTON MASSACHUSETTS 02110
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
HAEMONETICS CORP [ HAE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/15/2026F546(1)D$56.295,401(2)D
Common Stock05/15/2026A27,535(3)A(4)32,936(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
2. This number includes unvested RSUs previously reported, 139 shares acquired by the reporting person on October 31, 2025 under the Haemonetics Corporation 2007 Employee Stock Purchase Plan (as amended and/or restated from time to time, the "ESPP") and 119 shares acquired by the reporting person on April 30, 2026 under the ESPP.
3. The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.
4. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
/s/ Thomas V. Powers, attorney-in-fact for Mr. Chan05/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR